Upload
adam-scarborough
View
220
Download
1
Embed Size (px)
Citation preview
Stephen W Fenwick MD FRCS Stephen W Fenwick MD FRCS
Aintree University Hospital
Liverpool, UK
Consultant Hepatobiliary Surgeon Consultant Hepatobiliary Surgeon
Belfast, September 2011
Irinotecan Loaded DC Beads as Neoadjuvant
Treatment of Resectable Colorectal Liver Metastases
DeclarationStephen Fenwick is a consultant to Biocompatibles UK LTD.
Plan
• Systemic chemotherapy in CRLM
• Targeted chemotherapy
• Phase II trial of targeted chemotherapy in resectable colorectal metastases (Paragon II study)
Five-year survival of English colorectal cancer patients
Morris EJA et al. Brit J Surg 2010; 97: 1110-8
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Su
rviv
al p
rob
abil
ity
Years
All Stage 4
All patients
All stage 3
All stage 4 resected n=3116
Patients with resected liver metastases All patients without resected metastases Dukes C Dukes D
Survival after liver resection for colorectal liver metastases
0.0
0.2
0.4
0.6
0.8
1.0
40003000200010000Survival Time
Cu
mu
lativ
e S
urvi
val
Survival stratified by year of surgery (1997–2005)
1997199819992000200120022003200420051997-censored1998-censored2000-censored2001-censored2002-censored2003-censored2004-censored2005-censored
Not due toselection bias
So why are wegetting better?
Lancet 2008; 371: 1007-1016
EPOC study
Study design
Randomize
SurgeryFOLFOX4 FOLFOX4
Surgery
6 cycles
(3 months)
N=364 patients
6 cycles
(3 months)
Nordlinger et al. Lancet 2008; 371: 1007-16
Progression-free survival in resected patients
HR= 0.73; CI: 0.55-0.97, p=0.025
Surgery only
Periop CT
33.2%
42.4%
+9.2%At 3 years
(years)
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk :104 152 85 59 39 24 10
93 151 118 76 45 23 6
Nordlinger et al. Lancet 2008; 371: 1007-16
Completeresponse
Majorresponse
Minorresponse
Correlation of outcome after hepatectomy to histologic response to neoadjuvant
chemotherapy
2008; 26: 5344-51
Blazer et al.
Secondary liver resection rates of metastases and tumour response
Studies including non-selected patients with mCRC (solid line) (r=0.74; p<0.001)
Studies including selected liver metastases only patients (no extrahepatic disease)(r=0.96; p=0.002)
Phase III studies including non-selected patients with mCRC (dashed line)(r=0.67; p=0.024)
Folprecht G, et al. Ann Oncol 2005;16:1311–1319
Res
ectio
n ra
te
Response rate
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.3 0.4 0.5 0.6 0.7 0.8 0.9
Response rates >70%in unresectable liver only patients equates>40% liver resectionrate
How to bring more patients to resection?
Downstage the disease to make it resectable
“Upstage” the surgical techniques
And / Or
What are the problems with pre-operative chemotherapy ?
Chemotherapy liver damage
‘Blue’ liver ‘Yellow’ liver
Oxaliplatin Irinotecan
Sinusoidal Obstruction Syndrome
Increased peri-operativebleeding
Steatohepatitis
Increased post operative liver
failure & 90 daymortality
Complications of surgery
Peri-op CT Surgery
Post-operative complications*
40 /159 (25.2%)
27 / 170 (15.9%)
Cardio-pulmonary failure 3 2
Bleeding 3 3
Biliary Fistula 12 5
(Incl Output > 100ml/d, >10d)
(9) (2)
Hepatic Failure 11 8
(Incl. Bilirubin>10mg/dl, >3d)
(10) (5)
Wound infection 4 4
Intra-abdominal infection 8 2
Need for reoperation 5 3
Other 25
16
Incl. post-operative death 1 patient 2 patients
*P=0.04Nordlinger et al. Lancet 2008; 371: 1007-16
EPOC Study (EORTC 40983)
**
*
*
*
"Complete response" : does it mean cure ?
Before treatment After 6 cycles of chemotherapy
?
Wait for it tocome back?
Macroscopic CR after chemotherapy: ~20% of cells in periphery are viable
Courtesy of Professors G Mentha and L Rubbia Brandt, University of Geneva
DangerousHalo
Too much pre-surgery chemotherapy
• Problems for the liver surgeon
• Excessive Oxaliplatin– Excessive bleeding at surgery
• Excessive Irinotecan– Increased risk of post operative liver failure and 90 day mortality
• Complete response– “Disappearing” tumours
Targeted chemotherapy?
What would be the advantages of DC bead TACE over conventional therapy?
• Single administration, so reduced hepatic and systemic toxicity?
• Targeted, so protecting ‘normal’ liver?
• Could be combined with metal filings to radio-locate disappearing lesions?
• Cheaper?
• Faster action, so possibly shorter delay from treatment to surgery?
Trial proposal
• Study to evaluate safety/toxicity of targeted neoadjuvant irinotecan DC beads in patients with resectable colorectal liver metastases
PARAGON II STUDY
Study Design
• Multicentre, open label, single arm phase II study
• Primary endpoint – tumour resectability at surgery (% with R0 resection)
• Secondary endpoints– Adverse events – Radiological response– Pathological response– Survival Competitive studies:
UK: New EPOC
EORTC 40051: BOS
Participating Centres
• Liverpool • Basingstoke• Paris (Villejuif)• Girona• Vienna
Pathology review at a single centre
Paragon II Trial Design
• 40 patients with easily resectable colorectal liver metastases
• One TACE using Irinotecan loaded beads
• Liver resection 4 weeks later
Paragon II Trial Design
• 100-300 micron Paragon beads, loaded with irinotecan during manufacture
• Aim to give 200mg
• Selective embolisation to stasis
• 18-80 yrs, not pregnant or lactating• Potentially resectable disease, confined to liver• Unilobar disease, <4 lesions• No chemotherapy up to 1 month previously• No other primary cancer within past 10 yrs• Not enrolled in another trial within 30 days• Adequate liver, and bone marrow function
– WCC>3, Platelets >100, Bilirubin<1.5x normal
– Prothrombin time not more than>50% of normal
Inclusion Criteria
• 18-80 yrs, not pregnant or lactating• Potentially resectable disease, confined to liver• Unilobar disease, <4 lesions• No chemotherapy up to 1 month previously• No other primary cancer within past 10 yrs• Not enrolled in another trial within 30 days• Adequate liver, and bone marrow function
– WCC>3, Platelets >100, Bilirubin<1.5x normal
– Prothrombin time not more than>50% of normal
Inclusion Criteria
Exclusion Criteria
• Extra-hepatic disease• Contraindications to Irinotecan• Active infection• Allergy to Contrast media• Contraindications to Hepatic Artery embolisation• Severe atherosclerosis
Baseline (PET)CT within 1 month of procedure
TACE
CT followed by liver resection
Follow up CT at 3, 6, 9 & 12 months.
4 weeks
Trial Schedule
Technical considerations
• PARAGON beads are easy to use
• 4 hour “life”
• Small tumours more difficulty to localise– Contrast enhanced US– C arm CT
Post embolization
• Pain and nausea expected• Pre procedure NSAIDs• Manage with IV anti-emetics at time of
embolisation• Post procedure IV Narcotics, Morphine via PCA, IV
paracetemol, NSAIDs, and occasionally Entonox • Intra arterial lidocaine
• Recruitment so far
Centre Recruited Embolized Laparotomy
Basingstoke 1 1 1Girona 3 3 3Liverpool 26 26 25
Paris 1 1 1
Vienna 8 8 8
39 patients 26/08/2011 1st patient 11/02/2009 1.3 patients/month
Recruitment
Recruitment
Patients treated with TACE (n = 39)
Included Patients (n = 48, intention to treat population)
Patients treated with surgery (n = 36, one patient is waiting for surgery)
Ineligible for TACE after inclusion (n = 9)
Ineligible for resection after TACE (n = 2)
12 months follow-up (n = 18)
Withdrawn after surgery (n = 11)
Patients excluded before TACE
• 9 patients excluded
– Bilobar metastases (2)– Withdrew consent (2)– Pulmonary metastases– Suspected HCC– Allergy to contrast– Unable to canulate segmental artery– Tumour vessels not seen at angiography
Patients excluded before resection
• 2 patients excluded
– Peritoneal disease at laparotomy
Paragon II Patient characteristics
• n = 48, 10 female (21%), 38 male (79%)
• Age ±SD at TACE visit: 62 ±11 years (range 36-78)
• 1-3 tumours at screening, average 1.33
• 1-4 tumours prior to TACE, average 1.4
• Longest diameter pre TACE 44 mm (range 9-100)
Withdrawn During 12M Follow-up
• 01-001 B-L Progressive disease (new lesions, p.hepatis, lung nodules) • 02-001 W-W Progressive disease (new lesion)• 01-007 JOD Progressive disease (new lesions)• 01-010 JHO Progressive at 12 months (target+non-trgt)• 01-014 V-L Progressive disease (new lesion)• 04-001 AMR Diagnosed as HCC by histology• 04-004 RAA Unrelated death (pneumomediastinum)• 01-016 C-G Progressive disease (new lesions)• 01-017 G-W Unrelated death (aspiration, organ failure)• 04-003 JAB Outcome after 12 months to be confirmed
• Primary Endpoint: tumour resectability of targeted tumours
(% of patients with R0 resection, i.e. >2mm clearance margin)
• Patients: R0 16/25 (64%),
R1 (<2mm) 9/25 (36%)
Paragon II R0 Resection
Serious Adverse Events
Two patient deaths– Acute pneumomediastinum, during surgery– Aspiration pneumonitis, post surgery in-patient stay
Eleven Serious Adverse Events– Post embolisation syndrome in 4 patients (15%, expected)– Pancreatitis (expected, TACE related, non-target embol.)– Biloma (expected, surgical complication, MHRA: TACE)– Urinoma (expected, surgical complication, not TACE related)– Paroxysmal atrial fibrillation (not TACE related)– Jaundice (due to recurrence, not TACE related)– Neck haematoma (anaesthetic line complication)– Aspiration pneumonitis (not TACE related)– No serious and unexpected events
CompleteMajorMinorNone
Outcomes
Histological tumour response (n=26)
16%
61%
23%
Surgical findings
• Often marked capsular ischaemia
• Increased inflammatory reaction around tumour
• Areas of ischaemia difficult to differentiate from tumour
• Ischaemic cholecystitis
Patient 1
• 62 year old male
• Previous Segment VIII resection in 2005, with recurrence at site
• Treated with 70mg Irinotecan
• Discharged at 48 hrs post procedure
Patient 1 - TACE
• Right anterior sectionectomy
• R0 resection• Complete tumour
necrosis
• Background steatosis, portal chronic inflammatory change
Patient 1 - 4 weeks post TACE
Patient 6
Known lesion segment 8
Pre-treatment 1 month post
PET-CT pre-treatment
Positive segment 8 Negative segment 4A
Patient 6 histopathology
Treated metastasis Untreated metastasis
Conclusion
• Neoadjuvant TACE with Paragon beads is feasible and safe, with acceptable adverse events
• R0 resection and tumour necrosis rates are encouraging
• No negative effects seen at surgery
Conclusion
• Future work – explore differential tumour response
• Future trials combining DC bead therapy with systemic chemotherapy are now awaited
Future trials?Resctable disease
• Randomized phase III study with neoadjuvant irinotecan DC bead TACE and perioperative systemic chemotherapy (primary endpoint being PFS)
Unresectable patients
• Randomized phase II study looking at benefit of addition of irinotecan DC bead TACE to systemic FOLFOX (primary endpoint being liver resection rate)
Thank you